ASPS-1, A Novel Cell Line Manifesting Key Features of Alveolar Soft Part Sarcoma

In vitro growth of alveolar soft part sarcoma (ASPS) and establishment of an ASPS cell line, ASPS-1, are described in this study. Using a recently developed xenograft model of ASPS derived from a lymph node metastasis, organoid nests consisting of 15 to 25 ASPS cells were isolated from ASPS xenograft tumors by capture on 70 &mgr;m filters and plated in vitro. After attachment to the substratum, these nests deposited small aggregates of ASPS cells. These cells grew slowly and were expanded over a period of 3 years and have maintained characteristics consistent with those of both the original ASPS tumor from the patient and the xenograft tumor including (1) presence of the alveolar soft part locus-transcription factor E3 type 1 fusion transcript and nuclear expression of the alveolar soft part locus-transcription factor E3 type 1 fusion protein; (2) maintenance of the t(X;17)(p11;q25) translocation characteristic of ASPS; and (3) expression of upregulated ASPS transcripts involved in angiogenesis (ANGPTL2, HIF-1-&agr;, MDK, c-MET, VEGF, and TIMP-2), cell proliferation (PRL, PCSK1), metastasis (ADAM9), as well as the transcription factor BHLHB3 and the muscle-specific transcripts TRIM63 and ITG&bgr;1BP3. This ASPS cell line forms colonies in soft agar and retains the ability to produce highly vascularized ASPS tumors in NOD.SCID/NCr mice. Immunohistochemistry of selected ASPS markers on these tumors indicated similarity to those of the original patient tumor as well as to the xenografted ASPS tumor. We anticipate that this ASPS cell line will accelerate investigations into the biology of ASPS including identification of new therapeutic approaches for treatment of this slow growing soft tissue sarcoma.

[1]  R. Shoemaker,et al.  Abstract 3415: Therapeutic targeting of the ASPL-TFE3 gene fusion in ASPS-1, a novel cell line derived from metastatic alveolar soft part sarcoma (ASPS) , 2010 .

[2]  Wei-Lien Wang,et al.  Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray , 2009, Histopathology.

[3]  R. Shoemaker,et al.  Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy , 2009, Journal of pediatric hematology/oncology.

[4]  R. Shoemaker,et al.  BMC Cancer BioMed Central Research article Gene expression profiling of alveolar soft-part sarcoma (ASPS) , 2009 .

[5]  E. Rankin,et al.  The role of hypoxia-inducible factors in tumorigenesis , 2008, Cell Death and Differentiation.

[6]  W. Stetler-Stevenson The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.

[7]  R. Shoemaker,et al.  Immunohistochemical Discrimination Between the ASPL-TFE3 Fusion Proteins of Alveolar Soft Part Sarcoma , 2008, Journal of pediatric hematology/oncology.

[8]  A. Lazar,et al.  Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma , 2007, Clinical Cancer Research.

[9]  S. Rocha Gene regulation under low oxygen: holding your breath for transcription. , 2007, Trends in biochemical sciences.

[10]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[11]  A. Folpe,et al.  Alveolar soft-part sarcoma: a review and update , 2006, Journal of Clinical Pathology.

[12]  N. Scamuffa,et al.  Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases , 2006, Medicinal research reviews.

[13]  A. Basak Inhibitors of proprotein convertases , 2005, Journal of Molecular Medicine.

[14]  Napoleone Ferrara,et al.  Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.

[15]  R. Shoemaker,et al.  Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts , 2004, Cancer Research.

[16]  P. Reynolds,et al.  Midkine Is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling* , 2004, Journal of Biological Chemistry.

[17]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[18]  D. Burkin,et al.  The muscle integrin binding protein (MIBP) interacts with α7β1 integrin and regulates cell adhesion and laminin matrix deposition , 2003 .

[19]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[20]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[21]  N. Seidah,et al.  Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. , 2002, The American journal of pathology.

[22]  Alfons Meindl,et al.  The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 , 2001, Oncogene.

[23]  R. Mayne,et al.  A Novel Muscle-Specific β1 Integrin Binding Protein (Mibp) That Modulates Myogenic Differentiation , 1999, The Journal of cell biology.

[24]  E. Vámos,et al.  Alveolar soft‐part sarcoma: Further evidence by FISH for the involvement of chromosome band 17q25 , 1998, Genes, chromosomes & cancer.

[25]  D. Steiner,et al.  Proteolytic Processing Mechanisms in the Biosynthesis of Neuroendocrine Peptides: The Subtilisin-like Proprotein Convertases , 1995, Frontiers in Neuroendocrinology.

[26]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[27]  F. W. Foote,et al.  Alveolar soft‐part sarcomas. Structurally characteristic tumors of uncertain histogenesis , 1952, Cancer.

[28]  F. Calvo,et al.  The potential anti-tumorigenic and anti-metastatic side of the proprotein convertases inhibitors. , 2009, Recent patents on anti-cancer drug discovery.

[29]  D. Burkin,et al.  The muscle integrin binding protein (MIBP) interacts with alpha7beta1 integrin and regulates cell adhesion and laminin matrix deposition. , 2003, Developmental biology.

[30]  H. Cohen,et al.  Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  M. Cumming,et al.  Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.

[32]  N. Seidah,et al.  Pro-protein convertases of subtilisin/kexin family. , 1994, Methods in enzymology.